A carregar...
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
Cirmtuzumab is a humanized monoclonal antibody (mAb) that targets ROR1, an oncoembryonic orphan receptor for Wnt5a found on cancer stem cells (CSCs). Aberrant expression of ROR1 is seen in many malignancies and has been linked to Rho-GTPase activation and cancer stem cell self-renewal. For patients...
Na minha lista:
| Publicado no: | Cell Stem Cell |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7001723/ https://ncbi.nlm.nih.gov/pubmed/29859176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.stem.2018.05.018 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|